RxDoctor Payments Data

Jose Cardona Ramirez, MD

Cardiovascular Disease · San Juan, PRNPI 1093740912

Payments from drug & device makers

$2,097in general payments, 2019–2025

Across 79 payments — averaging $26.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Johnson & Johnson$341
  • E.r. Squibb & Sons, L.L.C.$216
  • Boston Scientific$98
  • Chiesi USA, Inc.$91
  • AstraZeneca$67
  • plus $117 from 5 others

What the payments were for

  • Food & beverage$2,097100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,097 in reported general payments places this provider in the 40th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$14,453
Medicare patients
68
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan116$76,814
FarxigaDapagliflozin Propanediol79$47,604
EliquisApixaban70$43,890
XareltoRivaroxaban56$34,886
BrilintaTicagrelor39$22,708
Irbesartan438$9,069
JanumetSitagliptin Phos/Metformin Hcl14$8,514
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide266$8,410
Metoprolol Succinate565$7,627
Repatha SureclickEvolocumab13$7,319
Diltiazem 24hr Er (Cd)Diltiazem Hcl123$4,493
Fenofibric AcidFenofibric Acid (Choline)69$2,692
Hydralazine Hcl210$2,668
SynthroidLevothyroxine Sodium23$1,871
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid17$1,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$67$70,312118 claims
Johnson & JohnsonXarelto$341$34,88656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →